利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.02 seconds)

    COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY 有权
    用于调节GAMMA-C细胞因子活性的组合物和方法

    公开(公告)号：US20160000877A1

    公开(公告)日：2016-01-07

    申请号：US14852240

    申请日：2015-09-11

    Applicant: Bioniz, LLC

    Inventor： Yutaka Tagaya ,  Nazli Azimi

    IPC: A61K38/20 ,  A61K47/48 ,  A61Q19/08 ,  A61Q19/00 ,  A61Q3/00 ,  A61K8/64 ,  A61Q7/00

    CPC classification number: C07K7/08 ,  A61K8/64 ,  A61K38/00 ,  A61K38/10 ,  A61K38/20 ,  A61K47/642 ,  A61K47/643 ,  A61Q3/00 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/08 ,  C07K7/06 ,  C07K14/52 ,  C07K14/54

    Abstract: The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

    Abstract translation: （IL-4），白细胞介素-7（IL-7），白介素9（IL-9），白细胞介素-15（IL-15），白细胞介素 和白细胞介素-21（IL-21）与重要的人类疾病如白血病，自身免疫疾病，胶原病，糖尿病，皮肤病，退行性神经元疾病和移植物抗宿主病（GvHD）有关。 因此，γc-细胞因子活性的抑制剂是有价值的治疗和美容剂以及研究工具。 本实施方案涉及基于用于抑制γc-细胞因子活性的共有γc-亚基结合位点的肽拮抗剂的设计。 在几个实施方案中，肽拮抗剂显示出Simul-Block活性，抑制多种γc-细胞因子家族成员的活性。

    SELECTIVE PEPTIDE ANTAGONISTS
    4.
    发明申请
    SELECTIVE PEPTIDE ANTAGONISTS 有权

    公开(公告)号：US20210082537A1

    公开(公告)日：2021-03-18

    申请号：US17083099

    申请日：2020-10-28

    Applicant: BIONIZ, LLC

    Inventor： Nazli Azimi ,  Yutaka Tagaya

    IPC: G16B15/00 ,  G16B20/00 ,  G16B35/00 ,  G16C20/60 ,  G01N33/50

    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

    PEPTIDE CONJUGATES
    5.
    发明申请
    PEPTIDE CONJUGATES 审中-公开

    公开(公告)号：US20180237475A1

    公开(公告)日：2018-08-23

    申请号：US15957806

    申请日：2018-04-19

    Applicant: BIONIZ, LLC

    Inventor： Yutaka Tagaya ,  Nazli Azimi

    IPC: C07K7/08 ,  A61Q7/00 ,  A61K38/20 ,  C07K14/52 ,  A61Q19/00 ,  A61Q19/08 ,  A61Q3/00 ,  C07K7/06 ,  A61K47/64 ,  A61K8/64 ,  A61K38/10 ,  A61K38/00

    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

    Peptide conjugates
    8.
    发明授权
    Peptide conjugates 有权

    公开(公告)号：US10808009B2

    公开(公告)日：2020-10-20

    申请号：US15957806

    申请日：2018-04-19

    Applicant: BIONIZ, LLC

    Inventor： Yutaka Tagaya ,  Nazli Azimi

    IPC: A61K38/00 ,  A61K38/10 ,  A61K38/20 ,  A61K47/64 ,  A61K8/64 ,  C07K7/08 ,  C07K7/06 ,  C07K14/54 ,  A61Q19/00 ,  A61Q19/08 ,  A61Q3/00 ,  A61Q7/00 ,  C07K14/52

    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

    METHODS OF DEVELOPING SELECTIVE PEPTIDE ANTAGONISTS
    10.
    发明申请
    METHODS OF DEVELOPING SELECTIVE PEPTIDE ANTAGONISTS 有权
    开发选择性肽拮抗剂的方法

    公开(公告)号：US20170051015A1

    公开(公告)日：2017-02-23

    申请号：US15179900

    申请日：2016-06-10

    Applicant: BIONIZ, LLC

    Inventor： Yutaka Tagaya ,  Nazli Azimi

    IPC: C07K7/08

    CPC classification number: C07K7/08 ,  A61K8/64 ,  A61K38/00 ,  A61K38/10 ,  A61K38/20 ,  A61K47/642 ,  A61K47/643 ,  A61Q3/00 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/08 ,  C07K7/06 ,  C07K14/52 ,  C07K14/54

    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

    Abstract translation: 公开了与多种配体 - 受体信号传导相互作用的选择性，特异性破坏相关的方法和组合物，例如涉及疾病的配体 - 受体相互作用。 这些相互作用可以涉及单个受体家族中的多个细胞因子或来自至少两个不同配体 - 受体家族的多个配体受体相互作用。 组合物可以包含具有包含两个或多个配体结合位点的序列片段的复合序列的多肽。 方法和组合物可以包括两个或更多个配体结合位点的序列片段，其被设置为保留取自序列片段的每个配体的二级结构。

Patent Agency Ranking